Year: 2020
Type: article
Abstract: Over the past two decades, measurements of carbon nanotube toxicity and biodistribution have yielded a wide range of results. Properties such as nanotube type (single-walled vs. multi-walled), purity, length, aggregation state, and functionalization, as well as route of administration, greatly affect both the biocompatibility and biodistribution of carbon nanotubes. These differences suggest that generalizable conclusions may be elusive and that studies must be material- and application-specific. Here, we assess the short- and long-term biodistribution and biocompatibility of a single-chirality DNA-encapsulated single-walled carbon nanotube complex upon intravenous administration that was previously shown to function as an in-vivo reporter of endolysosomal lipid accumulation. Regarding biodistribution and fate, we found bulk specificity to the liver and >90% signal attenuation by 14 days in mice. Using near-infrared hyperspectral microscopy to measure single nanotubes, we found low-level, long-term persistence in organs such as the heart, liver, lung, kidney, and spleen. Measurements of histology, animal weight, complete blood count; biomarkers of organ function all suggest short- and long-term biocompatibility. This work suggests that carbon nanotubes can be used as preclinical research tools in-vivo without affecting acute or long-term health.
Source: PLoS ONE
Language: English
Subfield: Biomedical Engineering
Field: Engineering
Domain: Physical Sciences
Open Access status: gold
Estimated APC paid: $1,695
Funders: National Science Foundation, U.S. Department of Defense, American Cancer Society, Commonwealth Foundation, Honorable Tina Brozman Foundation, Memorial Sloan-Kettering Cancer Center, Pershing Square Sohn Cancer Research Alliance, Cycle for Survival, National Institutes of Health, Weill Cornell Medical College, National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Advancing Translational Sciences, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Awards: G2051006376, G2295061683, G289723095, G372934033, G4102770861, G4583515593, Transient Metabolite Detection for Single-Cell Metabolomics and Diagnostics, G5109122429, MODELING HUMAN HEPATOCELLULAR CARCINOMA IN HUMANIZED MICE, CAREER: A Quantitative Nanosensor to Measure Redox Potential in Living Systems, P-selectin-Mediated Targeting of PI3K Nanomedicines to the Tumor Microenvironment, G613936551, G6671297155, G675646491, G6812410181, G7662121392, Identification of Hepatitis B Virus permissiveness factors, G7727211728, Renal tubule-specific nanotherapeutics for acute kidney injury, Modeling Hepatoblastoma using pluripotent stem cell derived hepatocyte-like cells, New Hepatocyte Model Systems to study Hepatitis B Virus Infection, G9000003249, G9000064224, G9000270641, Cancer Center Support Grant, Clinical and Translational Science Center
OpenAlex ID: W3022645129